| 2019 | | 2019 Clinical Practice Guidelines for Type 2 Diabetes Mellitus in Korea | 김대중 |
| 2015 | | A Korean version of the Appraisal of Diabetes Scale (ADS-K): psychometric evaluation with a population of Koreans with type 2 diabetes. | 이관우, 이은현, 한승진 |
| 2024 | | A Multicenter, Randomized, Open-Label Study to Compare the Effects of Gemigliptin Add-on or Escalation of Metformin Dose on Glycemic Control and Safety in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Treated with Metformin and SGLT-2 Inhibitors (SO GOOD Study) | 김혜진 |
| 2020 | | A New Objective Health Numeracy Test for Patients with Type 2 Diabetes: Development and Evaluation of Psychometric Properties | 이관우, 이은현 |
| 2020 | | A New Self-management Scale with a Hierarchical Structure for Patients with Type 2 Diabetes | 이관우, 이은현 |
| 2015 | | A prospective, randomized, multicenter trial comparing the efficacy and safety of the concurrent use of long-acting insulin with mitiglinide or voglibose in patients with type 2 diabetes. | 이관우 |
| 2022 | | A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes Mellitus | 한승진 |
| 2005 | | Alterations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9 in patients with type-2 diabetes. | 김대중, 송경은, 이관우 |
| 2018 | | ApoB/ApoA-I ratio is independently associated with carotid atherosclerosis in type 2 diabetes mellitus with well-controlled LDL cholesterol levels | 김대중 |
| 2016 | | Association between insulin resistance and impairment of FGF21 signal transduction in skeletal muscles | 강엽, 김대중, 김혜진, 이관우, 전자영, 최성이, 한승진 |
| 2018 | | Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study | 김대중, 김혜진, 이관우, 한승진 |
| 2016 | | Basal-prandial versus premixed insulin in patients with type 2 diabetes requiring insulin intensification after basal insulin optimization: A 24-week randomized non-inferiority trial | 이관우 |
| 2018 | | Blood adiponectin levels are not associated with risk of cardiovascular events in patients with type 2 diabetes | 김대중, 김혜진, 이관우, 전자영, 하경화, 한승진 |
| 2020 | | Body Fat Is Related to Sedentary Behavior and Light Physical Activity but Not to Moderate-Vigorous Physical Activity in Type 2 Diabetes Mellitus | 김혜진 |
| 2012 | | C1q/TNF-related protein-3 (CTRP-3) and pigment epithelium-derived factor (PEDF) concentrations in patients with type 2 diabetes and metabolic syndrome | 이관우 |
| 2018 | | Can persistent organic pollutants distinguish between two opposite metabolic phenotypes in lean Koreans? | 김대중, 하경화 |
| 2020 | | Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study | 김대중, 하경화 |
| 2022 | | Cardiovascular disease in patients with type 2 diabetes | 김대중, 전자영 |
| 2017 | | Cardiovascular events associated with second-line anti-diabetes treatments: analysis of real-world Korean data | 김대중, 하경화 |
| 2018 | | Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study | 김대중 |
| 2023 | | Cardiovascular Outcomes according to Comorbidities and Low-Density Lipoprotein Cholesterol in Korean People with Type 2 Diabetes Mellitus | 김혜진 |
| 2021 | | Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data | 김대중 |
| 2021 | | Cardiovascular safety of sodium glucose cotransporter 2 inhibitors as add-on to metformin monotherapy in patients with type 2 diabetes mellitus | 김대중, 전자영, 하경화 |
| 2022 | | Characteristics and Clinical Course of Diabetes of the Exocrine Pancreas: A Nationwide Population-Based Cohort Study | 김대중, 김혜진, 이관우, 이나미, 전자영, 한승진 |
| 2019 | | Circulating calcium levels and the risk of type 2 diabetes: a systematic review and meta-analysis | 김대중 |
| 2014 | | Clinical and economic outcomes in medication-adherent and -nonadherent patients with type 2 diabetes mellitus in the Republic of Korea. | 김대중, 김혜진, 이관우, 전기홍, 전자영, 한승진 |
| 2007 | | Clinical characteristics of Korean type 2 diabetic patients in 2005. | 김대중, 이관우 |
| 2020 | | Clinical Outcomes of COVID-19 Patients with Type 2 Diabetes: A Population-Based Study in Korea | 김대중 |
| 2022 | | Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study | 김혜진 |
| 2020 | | Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study | 김혜진 |
| 2016 | | Comparison of screening scores for diabetes and prediabetes | 김대중 |
| 2006 | | Decrement of postprandial insulin secretion determines the progressive nature of type-2 diabetes. | 김혜진 |
| 2007 | | Depot-specific regulation of perilipin by rosiglitazone in a diabetic animal model. | 김대중, 김혜진, 이관우 |
| 2017 | | Dipeptidyl Peptidase-4 Inhibitors and Risk of Heart Failure in Patients With Type 2 Diabetes Mellitus: A Population-Based Cohort Study | 김대중, 김혜진, 박래웅, 윤덕용, 이관우, 한승진 |
| 2018 | | Dipeptidyl Peptidase-4 Inhibitors and the Risk of Pancreatitis in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study | 김대중, 김혜진, 이관우, 한승진 |
| 2012 | | Direct medical costs for patients with type 2 diabetes and related complications: a prospective cohort study based on the Korean National Diabetes Program | 김대중, 김혜진, 이관우, 전기홍, 한승진 |
| 2022 | | Drug Repositioning Using Temporal Trajectories of Accompanying Comorbidities in Diabetes Mellitus | 전자영 |
| 2016 | | Economic Burden of Hypoglycemia in Patients with Type 2 Diabetes Mellitus from Korea | 김대중 |
| 2017 | | Effect of sarpogrelate, a selective 5-HT2A receptor antagonist, on characteristics of coronary artery disease in patients with type 2 diabetes | 강두경, 김혜진, 한승진 |
| 2021 | | Effect of teneligliptin versus sulfonylurea on major adverse cardiovascular outcomes in people with type 2 diabetes mellitus: A real-world study in Korea | 김대중, 하경화 |
| 2021 | | Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study | 김대중, 이나미, 하경화, 한승진 |
| 2011 | | Effects of a cardiovascular risk reduction intervention with psychobehavioral strategies for Korean adults with type 2 diabetes and metabolic syndrome. | 김대중 |
| 2017 | | Effects of combination of change in visceral fat and thigh muscle mass on the development of type 2 diabetes | 한승진 |
| 2023 | | Effects of dapagliflozin compared with glimepiride on body composition in Asian patients with type 2 diabetes inadequately controlled with metformin: The BEYOND study | 이관우 |
| 2017 | | Effects of foot complications in patients with Type 2 diabetes mellitus on public healthcare: An analysis based on the Korea National Diabetes Program Cohort | 이관우, 전기홍 |
| 2007 | | Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. | 김대중, 이관우 |
| 2019 | | Effects of sarpogrelate on microvascular complications with type 2 diabetes | 김대중, 박인휘 |
| 2017 | | Effects of valsartan and amlodipine on oxidative stress in type 2 diabetic patients with hypertension: a randomized, multicenter study | 김대중, 김혜진, 이관우, 한승진 |
| 2023 | | Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension | 김혜진 |
| 2017 | | Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study) | 이관우 |
| 2018 | | Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial | 이관우 |
| 2019 | | Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial | 이관우 |
| 2023 | | Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study | 김대중, 하경화 |
| 2023 | | Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia | 김대중, 하경화 |
| 2023 | | Empagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in routine care in East Asia: Results from the EMPRISE study | 김대중, 하경화 |
| 2018 | | Failure of monotherapy in clinical practice in patients with type 2 diabetes: The Korean National Diabetes Program | 김대중, 김혜진, 이관우, 전자영, 한승진 |
| 2011 | | Fat redistribution preferentially reflects the anti-inflammatory benefits of pioglitazone treatment. | 김혜진 |
| 2022 | | Healthcare resource utilization in patients treated with empagliflozin in East Asia | 김대중, 하경화 |
| 2000 | | HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. | 김현만, 정윤석 |
| 2019 | | Hospital-Based Korean Diabetes Prevention Study: A Prospective, Multi-Center, Randomized, Open-Label Controlled Study | 이관우 |
